Brief Description:

First-in-Human safety and tolerability study in adult participants with confirmed PKD1 mutation-associated ADPKD. The anticipated number of participants across 3 Part B (SAD - ADPKD) cohorts is approximately 18 participants. On Day 1, each participant will receive PYC-003 as a single IV infusion.

Type of research:

Clinical Trial

Your time commitment:

Other

Consumers re-imbursed?

Expenses covered

Who are researchers looking for?

Person with early stage kidney disease

Contact for more info:

Email: [email protected]

Phone: +61448041918

Return to research listing page